Table 2: Prescribing Information for Glucagon-like Peptide-1 Receptor Agonists and Sodium–Glucose Cotransporter 2 Inhibitors (Based on US Labels).

Generic Name	Brand Name	Doses	Schedule	Additional Information
GLP-1R agonists (all injectables except Rybelsus)
Exenatide	Byetta	5, 10 µg	Twice daily	32 G pen needles supplied separately; prefilled, single-use pen
Exenatide extended release	Bydureon	2 mg	Weekly	23 G, hidden needles pre-attached; prefilled autoinjector device
Dulaglutide	Trulicity	0.75, 1.5 mg	Weekly	29 G hidden needles pre-attached; prefilled autoinjector device
Liraglutide	Victoza	0.6, 1.2, 1.8 mg	Daily	Indicated to reduce the risk of MACE in T2D with established CVD; 32-G pen needles supplied separately; prefilled, multi-dose pen
Lixisenatide	Adlyxin	10, 20 µg	Daily	≤8 mm pen needles supplied separately; prefilled, single-use pen
Semaglutide (injection)	Ozempic	0.25, 0.5 mg	Weekly	32 G 4 mm pen needles included; prefilled, single-use pen
Semaglutide (oral)	Rybelsus	3, 7, 14 mg	Daily	Only oral GLP-1RA available
SGLT-2 inhibitors (all oral tablets, most available in fixed-dose combinations with metformin)
Canagliflozin	Invokana	100, 300 mg	Daily	Indicated to reduce risk of MACE in T2D and established CVD; also indicated to reduce risk of progression of kidney disease, CV death and HF hospitalisation in T2D and diabetic kidney disease with macroalbuminuria
Dapagliflozin	Farxiga	5, 10 mg	Daily	Indicated to reduce risk of HF hospitalisation in T2D with established CVD or multiple CV risk factors
Empagliflozin	Jardiance	10, 25 mg	Daily	Indicated to reduce risk of CV death in T2D with established CVD
Ertugliflozin	Steglatro	5, 15 mg	Daily	CV outcomes trial (VERTIS-CV; NCT01986881)

CV = cardiovascular; CVD = cardiovascular disease; GLP-1R = glucagon-like peptide-1 receptor; GLP-1RA = glucagon-like peptide-1 receptor agonist; HF = heart failure; MACE = major adverse cardiovascular events; SGLT-2 = sodium–glucose cotransporter 2; T2D = type 2 diabetes.